Clinical trial
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients
NCT03137264
Study timeline
Study start (actual)2017-10-24Date precision: day
Registry last updated2019-11-07
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancerunresolved
Interventions
OtherDRUG
Sponsors & collaborators
AstraZenecalead sponsor
Medpace, Inc.collaborator
Mapped research locations
SeattleWashington, United States2ChicagoIllinois, United States1Los AngelesCalifornia, United States1MontrealQuebec, Canada1EdmontonAlberta, Canada1Fort LauderdaleFlorida, United States1HonoluluHawaii, United States1AnaheimCalifornia, United States1AshevilleNorth Carolina, United States1BoiseIdaho, United States1Santa RosaCalifornia, United States1KetteringOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03137264 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.